The Effects of Growth Hormone and/or Testosterone in Healthy Elderly Men: A Randomized Controlled Trial by Giannoulis, Manthos et al.
The Effects of Growth Hormone and/or Testosterone in
Healthy Elderly Men: A Randomized Controlled Trial
Manthos G. Giannoulis, Peter H. Sonksen, Margot Umpleby, Louise Breen, Claire Pentecost,
Martin Whyte, Carolyn V. McMillan, Clare Bradley, and Finbarr C. Martin
Departments of Diabetes and Endocrinology (M.G.G., L.B., C.P., M.U., M.W., P.H.S.) and Ageing and Health (F.C.M.), GKT
School of Medicine, King’s College London, St. Thomas’ Hospital, London SE1 7EH, United Kingdom; and Health Psychology
Research,, Psychology Department, Royal Holloway, University of London (C.V.M., C.B.), Egham, Surrey TW20 0EX, United
Kingdom
Context: Declines in GH and testosterone (Te) secretion may con-
tribute to the detrimental aging changes of elderly men.
Objective: To assess the effects of near-physiological GH with/with-
out Te administration on lean body mass, total body fat, midthigh
muscle cross-section area, muscle strength, aerobic capacity, condi-
tion-specific quality of life (Age-Related Hormone Deficiency-Depen-
dent Quality of Life questionnaire), and generic health status (36-
Item Short-Form Health Survey) of older men.
Design, Settings, and Participants: A 6-month, randomized, dou-
ble-blind, placebo-controlled trial was performed on 80 healthy, com-
munity-dwelling, older men (age, 65–80 yr).
Interventions: Participants were randomized to receive 1) placebo
GH or placebo Te, 2) recombinant human GH (rhGH) and placebo Te
(GH), 3) Te and placebo rhGH (Te), or 4) rhGH and Te (GHTe). GH
doses were titrated over 8 wk to produce IGF-I levels in the upper half
of the age-specific reference range. A fixed dose of Te (5 mg) was given
by transdermal patches.
Results:Leanbodymass increasedwithGHTe (P0.008) andGH (P
0.004), comparedwith placebo. Total body fat decreasedwithGHTe only
(P 0.02).Midthighmuscle (P 0.006) and aerobic capacity (P 0.001)
increased only after GHTe. Muscle strength changes were variable; one
of six measures significantly increased with GHTe. Significant treat-
ment group by time interactions indicated an improved Age-Related
HormoneDeficiency-DependentQuality of Life questionnaire score (P
0.007) in theGHandGHTegroups.Bodilypain increasedwithGHalone,
as determinedby theShort-FormHealthSurvey (P0.003). Therewere
no major adverse effects.
Conclusion: Coadministration of low dose GH with Te resulted in
beneficial changes being observed more often than with either GH or
Te alone. (J Clin Endocrinol Metab 91: 477–484, 2006)
INCREASES IN POPULATION life expectancy bring ad-ditional years of disability (1). Sarcopenia, due to age-
associated decreases in skeletal muscle mass and strength (2,
3), is associated with impaired mobility, falls, fractures, and
higher mortality rates (4, 5). Aging-associated increases in
proportional total body and intraabdominal visceral fat (VF)
are risk factors for cardiovascularmorbidity andmortality (6,
7). These detrimental aging changes are a challenge to indi-
viduals and health care providers.
Age-associated sarcopenia is multifactorial. Hormonal de-
cline may be a factor. GH secretion falls during adulthood;
more than 30% of elderly people have circulating IGF-I levels
below the young-normal range (8). Testosterone (Te) levels
also decline progressively; average levels are 30% lower by
age 70 yr (9). In young adults, a deficiency of either GH or
Te produces changes similar to the aging phenotype, which
reverse after GH and/or Te replacement (10, 11). Thus, ag-
ing-associated declines in GH or Te secretionmay contribute
to detrimental aspects of aging (12, 13).
Several intervention trials have shown that although either
GHor Te individually can have anabolic effects in older adults,
this may not always translate into functional improvements
(13–17).Olderpeoplearemore sensitive toGH, sideeffectshave
been related to circulating IGF-I levels (18), andmost GH stud-
ies have been hampered by side effects associated with high
doses, not tailored to individual responsiveness (19).
There is evidence for synergistic anabolic action between
GH and Te (20). mRNA for IGF-I increases after adminis-
tration of Te to healthy elderly men and decreases in healthy
young men after they become hypogonadal (21). This sug-
gests that combining GH and Te may have clinical utility,
and indeed, since we embarked on this study, several in-
vestigations of this therapeutic approach have been reported
(22, 23). We hypothesized that by selecting healthy menwith
relatively low circulating IGF-I and Te levels and individu-
ally tailoring low-dose GH replacement, this combined ap-
proach might reverse some of the aging-associated changes
without significant adverse effects.
Subjects and Methods
Subjects
Participants were volunteer, healthy, community-dwelling, elderly
men (65–80 yr) without significant mobility difficulties or disability,
recruited through newspaper articles. The selection and retention of
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participants in the study are illustrated in Fig. 1. Exclusion criteria were
clinically significant pulmonary, cardiac, hepatic, renal, neurological, or
psychiatric disease; uncontrolled hypertension or diabetes; past or
present pituitary disease; receiving corticosteroid treatment; obesity
[bodymass index (BMI),30 kg/m2]; currently evidentmalignancy; any
history of prostate cancer; elevated age-specific level of prostate-specific
antigen (PSA; 4.5 ng/ml); or palpable prostate nodule. From volun-
teers meeting these criteria and whose circulating IGF-I levels were
lower than the 50th percentile for the local age-specific reference range
[roughly 2 sd below the mean for young adults 30–40 yr (145 ng/ml;
19.0 nmol/ml)], we selected 80 participantswith the lowest Te levels, but
excluded those with frank Te deficiency (173 ng/dl; 6.0 nmol/liter).
The mean screening Te level of our study participants was 397.6  10
ng/dl. The research ethics committee ofGuy’s and St. Thomas’Hospitals
approved the protocol. Participants provided written informed consent.
Study protocol
The study was a double-blind, randomized, placebo-controlled trial.
At baseline (visit 0) participants gave fasting blood samples for routine
full blood count, liver function tests, urea and electrolytes, IGF-I, IGF-
binding proteins 1 and 3 (IGFBP-1 and IGFBP-3), Te, estradiol, LH, FSH,
TSH, SHBG, PSA, glucose, insulin, and C peptide. Participants then had
their aerobic capacity (VO2max) and body composition measured, and
after a lunch break of about 2 h, their muscle strength measured as
described below.
At visit 1 (treatment wk 0), participants were trained to self-admin-
ister their treatment, which commenced that day and continued daily for
6months.We used a dose titration regimen for the administration of GH
to minimize possible adverse effects. Consequently, subjects had a reg-
ular follow-up on wk 2 (visit 2), wk 4 (visit 3), wk 6 (visit 4), and wk 8
(visit 5) at which time their IGF-I levels weremeasured, and theGHdose
was adjusted according to our predefined protocol (see below). Two
more visits were conducted at 3 months (visit 6) and at the end of the
study at 6 months (visit 7). At all follow-up visits, subjects were assessed
for possible side effects, and blood pressure and percent body fat were
measured. All baseline measurements were repeated again at the end of
the study at 6 months (visit 7).
Te (5 mg) or placebo was given by transdermal patches (Watson
Laboratories, Inc., Salt Lake City, UT). Active recombinant human GH
(rhGH) or placebo (Norditropin Simplex, Novo Nordisk, Copenhagen,
Denmark) was given by sc injection at bedtime. Treatment group allo-
cation was determined by randomization into four groups to receive 1)
placebo rhGH injections and placebo Te patches (group Pl; n  20), 2)
rhGH injections and placebo Te (group GH; n  18), 3) Te and placebo
rhGH injections (group Te; n  23), or 4), rhGH and Te (group GHTe;
n  19). Randomization using computer-generated preallocated study
numbers was performed by a dispensing pharmacist who was not oth-
erwise involved in the study.
Titration of rhGH doses
The active or placebo rhGH starting dose was 0.1 mg/d. Incremental
dose adjustments to 0.2, 0.4, 0.8, and amaximumof 1.2mg/dweremade
at the 2-weekly (visits 2–5), according to participants’ circulating IGF-I
levels and a predefined protocol; the target range was 141–252 ng/ml,
equivalent to the upper half of the age-specific reference range or close
to themean for young adults 30–40 yr old. Doses producing IGF-I levels
just above target were left unaltered if well tolerated. Doses were re-
duced if the participant reported probable side effects, or if the IGF-I
level was above 380 ng/ml (equivalent to the 75th percentile of the
young adult range; conversion: nanograms per milliliter to nanomoles
per liter, multiply by 0.131).
Blindness of the treatment
Every reasonable attempt was made to ensure true double-blind
conditions throughout. Adjustment ofGHandplacebo dosesweremade
by our endocrine nurse specialist (ENS), who checked the IGF-I levels
of the subjects at each visit, and she adjusted the dose of GH according
to a predefined protocol. She was blinded to the treatments and, indeed,
increased the placebo dose when IGF-I values failed to rise, but did not
exceed a predefined upper dose limit. She also reduced the GH or
placebo dose when possible adverse effects were reported. When any
additional specialized advicewas needed, she consulted a second doctor
who was not involved in the study. Placebo rhGH vials and placebo Te
patches were indistinguishable from the active treatment and were
provided by the same manufacturer. To secure and maintain blindness,
treatment drugs were dispensed for each subject in identical packages
by the Department of Pharmacy. Subjects picked up their supplies after
each study visit in a quantity sufficient to last until their next visit. The
medical doctor responsible for the outcome measurements at baseline
and at the 6-month visit (M.G.G.) was not involved in this part of the
study and was blind to treatment groups throughout.
Assessment of adverse events and treatment side effects
At visits 2–7, participants completed a questionnaire delivered by the
ENS, recording all possible adverse events and likely treatment side
effects based on previous studies. An independent endocrinologist with
access to IGF-I levels and questionnaires, but not otherwise involved
with the study, agreed on dose amendments or withdrawal from the
study with the ENS. PSA and hemoglobin measurements were repeated
after 3 (visit 6) and 6 months (visit 7).
Assays
IGF-I was measured by a two-site chemiluminescence immunoassay
on a Advantage analyzer (Nichols Institute, San Juan Capistrano, CA)
FIG. 1. Selection and retention of
participants in the study.
478 J Clin Endocrinol Metab, February 2006, 91(2):477–484 Giannoulis et al. • GH and/or Testosterone in the Elderly
and IGFBP-3 by a commercial DSL 6600 ACTIVE IGFBP-3 (immunora-
diometric assay) coated tube assay kit. The intraassay coefficient of
variation (CV) was less than 5.2% for IGF-I and less than 3.9% for
IGFBP-3. The interassay CVs were less than 7.4% and 1.9% for IGF-I and
IGFBP-3, respectively. Total Te, estradiol, FSH, LH, TSH, free T4, free T3,
and PSA were all measured on the ADVIA Centaur analyzer (Bayer,
Tarrytown, NY). The intraassay CV for Te was 5.2%, and that for es-
tradiol was 12.1%; the interassay CVs were 6.0% and 6.1%, respectively.
SHBG was measured by an immunometric assay on an Immulite ana-
lyzer (Diagnostic Products Corp., Los Angeles, CA). Free Te (FTe) was
calculated from the formula: FTe (pmol/liter)  6.11  [2.38  log
(SHBG nmol/liter)]  Te (nmol/liter) result  10. Glucose was mea-
sured by an oxygen rate method employing an oxygen electrode (Beck-
man Coulter, Fullerton, CA). The intraassay CVs ranged from 1.2–6.1%.
Outcome measures
Body composition. Weight was measured using a Tanita (Arlington
Heights, IL) electronic scale, height by a standing stadiometer, and
waist/hip ratios were calculated from the mean of three tape measure-
ments. Total body fat (FBM), lean body mass (LBM), and percent body
fat were calculated from dual-energy x-ray absorptiometry scans (QDR-
4500W scanner, Hologic, Inc., Waltham, MA) (24). Midthigh muscle
cross-sectional area (CSA), cross-sectional abdominal VF, and sc fat (SC)
were measured by computed tomography (Philips-Tomoscan AV, Phil-
ips Electronic Instruments, Mahway, NJ). One-slice scans in the middle
abdomen through the L4/L5 disc space and in the thigh midway be-
tween the anterior superior iliac spine to the superior border of the
patella were performed (24).
Cardio-respiratory fitness (VO2max). VO2max was measured using a step-
wise maximal exercise test on an electromagnetically braked bicycle
ergonometer (Lode Excalibur Sport, Groningen, The Netherlands) using
a computerized open-loop gas analyzer system (Medical Graphics
Corp., St. Paul, MN), as described (25). The peak VO2max was recorded
with participants exercising to exhaustion.
Muscle strength. Strength was measured isokinetically (concentric knee
flexion/extension at angular velocities of 60, 90, and 180°/sec) using a
Kin-Commodel 125E (Chattecx, Chattanooga, TN) isokinetic dynamom-
eter. Peak torque was calculated using Kin-Com computer software. In
addition, the isometric peak force values were obtained for the knee
extensors at an angle of 90° and hand grip. The best of the threemaximal
efforts was used as the peak force.
Patient-reported outcomes. Patient-reported outcomes were assessed with
the specially developed condition-specific Age-Related Hormone Defi-
ciency-Dependent Quality of Life questionnaire (A-RHDQoL) (26), the
generic health-status measure Short-Form 36 (SF-36) (27), and the ge-
neric Well-Being Questionnaire (W-BQ12) (28), and sexual dysfunction
was measured by the Arizona Sexual Experience questionnaire (29).
Statistical analyses
Power calculations indicated that group sizes of 19 and 13 would be
needed to detect mean differences over 6 months of 2.5% in LBM and
20% in muscle strength, respectively (  0.05;   0.90). Baseline
differences between groups were analyzed by one-way ANOVA, em-
ploying the Bonferroni correction. Differences between treatment
groups in changes of outcome measures after 6 months of treatment
were analyzed by analysis of covariance (ANCOVA) adjusting for the
value of the dependent variable at baseline and age. Each treatment
group was compared with placebo and with each other. Differences in
final rhGH doses were assessed by Mann-Whitney U test. Linear re-
gression analysis assessed relationships between variables. P 0.05 was
considered significant after a Bonferroni correction. Results are ex-
pressed as the mean  sem. These data were analyzed using the Stata
6.0 computer program (Stata Corp., College Station, TX).
A mixed model, repeated measures ANOVAwas conducted on each
of the following: A-RHDQoL average weighted impact score, the SF-36
(eight subscales), W-BQ12 (three subscales), and the Arizona Sexual
Experience questionnaire total score, both with and without covariates:
BMI, Te, and IGF-I levels (at baseline and end point) and age. Planned
orthogonal contrasts were conducted: 1) placebo vs. the three treatment
groups, 2) GHTe vs. GH and Te groups, and 3) GH vs. Te group. These
analyses were performed using SPSS for Windows, release 9.0 (SPSS,
Inc., Chicago, IL).
Results
There were no differences between groups in baseline
body composition, hormonal, or clinical measures (Table 1).
We intended an intention to treat approach to statistical
analysis, including all available data from all participants.
Eleven participants did not complete the study. Five were
excluded soon after commencement because their baseline
visit PSA levelsmet the revised exclusion criterion (above the
revised local age-specific reference range of 4.5 ng/ml). They
had been initially included when at screening their PSA
levels were below the age-specific upper normal limit of 6
ng/ml, the criterion initially adopted, but subsequently re-
vised down to the more cautious lower level. Three were
withdrawn because of adverse events, and three withdrew
themselves for personal reasons. Outcome data were not
available for these six participants. Thus, analysis of the
remaining 69 participants is both an intention to treat and a
per-protocol analysis (Pl, n  16; GH, n  16; Te, n  21;
GHTe, n  16; Fig. 1). The significant changes reported for
hormone profile, body composition, muscle strength, and
VO2max represent changes for each treatment group from
baseline compared with changes in the placebo group.
Hormone profile
IGF-I levels increased significantly from 102.9  6.4 to
193.4  10.6 ng/ml in the GH group (P  0.0001) and from
102.4  6.8 to 209.5  15 ng/ml in the GHTe group (P 
0.0001), reaching the target IGF-I levels with similar final
rhGHdoses (GH, 0.54 0.06mg/d:GHTe, 0.52 0.06mg/d;
P 0.80; Fig. 2A). IGFBP-3 also increased from3297.2 128.8
to 3688.3 174.5 ng/ml (P 0.0001) and from 3482.8 175.1
to 3941.9  186.6 ng/ml in both GH and GHTe groups,
TABLE 1. Baseline characteristics of the participants
Pl (n  20) GH (n  18) Te (n  23) GHTe (n  19) All (n  80) P
Age (yr) 69.5 (0.7) 70.7 (0.7) 70.3 (0.6) 70.3 (0.6) 70.2 (0.3) 0.81
Weight (kg) 81.2 (9.3) 76.9 (9.3) 79.3 (11) 80.8 (11) 79.7 (1.1) 0.52
BMI (kg/m2) 26.7 (0.5) 25.6 (0.6) 26.9 (0.7) 26.2 (0.7) 26.5 (0.3) 0.53
IGF-I (ng/ml) 100.7 (6.1) 102.2 (5.3) 109.1 (6.2) 102.4 (6.7) 103.8 (3.0) 0.77
IGFBP-3 (ng/ml) 3114 (221) 3297 (128) 3272 (155) 3482 (175) 3268 (84) 0.73
Te (ng/dl) 432 (31) 487 (39) 498 (36) 495 (41) 478 (18) 0.54
FTe (pg/ml) 107 (7.9) 115 (8.3) 115 (6.8) 123 (11.2) 114 (4) 0.38
All values are presented as mean (SE). The P value is for the overall comparison between groups. To convert Te to nmol/liter, multiply values
by 0.0347. To convert IGF-I to nmol/liter, multiply by 0.131. To convert FTe to pmol/liter, multiply by 3.47. Pl, Placebo.
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respectively. Mean Te levels increased from 498.5  34.5 to
714.6  95.1 ng/dl in the Te group (P  0.029) and from
495.6  37.4 to 659.9  80.6 ng/dl in the GHTe group (P 
0.05; Fig. 2B). FTe levels increased significantly only in the Te
group (P  0.019). No changes in Te or FTe occurred in the
Pl or GH groups or in estradiol levels in any group. LH and
FSHwere suppressed in the Te andGHTe groups (P 0.003).
Outcome measures
Body composition. Compared with placebo, no significant
changes in BMI or waist/hip ratio were noted in any group,
but LBM increased by 2.0  0.5 kg in the GH group (P 
0.004) and by 1.8 0.5 kg in the GHTe group (P 0.007; Fig.
3A). Post hoc analysis revealed that the mean increase in the
GHTe group was significantly greater than that in the Te
group (P  0.031), but not to that in the GH group. FBM
decreased significantly by 1.8 0.4 kg (P 0.02) with GHTe,
but not with GH (1.4 0.5 kg; P 0.09) or Te alone (P 0.86;
Fig. 3B). Statistically insignificant decreases in SC and VF
were observed in the GH and GHTe groups (data not
shown). A significant increase in midthigh muscle CSA oc-
curred only with GHTe (7.0  3.0%; P  0.006; Fig. 3C).
Muscle strength. Of all measures, the only significant change
in strength was an increase in concentric knee flexion at
120°/sec in the GHTe group (P  0.038). Otherwise, all
groups had nonsignificant reductions in muscle strength
over 6 months of about 5–10% for extension and somewhat
less for flexion (Table 2).
VO2max. VO2max increased, compared with that in the pla-
cebo group, in the GHTe group from 24  0.9 to 29.5  1.2
ml/kgmin (P  0.001; Fig. 3D). The VO2max failed to in-
crease significantly after GH from 25.8 0.9 to 27.1 1.1 and
Te from 23.6 1 to 24.4 1 ml/kgmin. The post hoc analysis
indicted that the mean increase in VO2max in the GHTe
groupwas significantly greater that that in the Te (P 0.001)
or GH (P  0.008) group.
Patient-reported outcomes. A significant group-by-time effect
was found for the A-RHDQoL average weighted impact
score [F(3,63) 4.39; P 0.007; analysis without covariates],
with planned contrasts showing that 1) placebo differed from
the three treatment groups [t(63)2.08; P 0.04]; 2) GHTe
did not differ significantly from the GH or Te group; and 3)
GH differed from the Te group [t(63)  2.17; P  0.03]. The
Te group reported a worsening of the negative impact of
age-related hormone deficiency on quality of life at the end
point, but the GH and GHTe groups showed an improve-
ment (Table 3). The overall group by time interaction was
considerably reduced by the introduction of covariates, but
was still significant (P  0.038). A significant group by time
effect was also found for SF-36 bodily pain [F(3,59)  5.27;
P  0.003; significance unaffected by covariates]; planned
contrasts showed that GH differed from Te [t(59)  3.43;
P 0.001], because bodily painworsened considerably in the
GH-only group by the endpoint, but improved slightly in the
Te and GHTe groups. There were no other significant group
by time effects on patient-reported outcomes.
Adverse events
Fifteen of 36 (41%) participants receiving rhGH experi-
enced adverse events probably related to rhGH. One with-
drew with carpal tunnel syndrome (GHTe group). Other
symptoms were mild and resolved within a few days of
rhGHdose reduction. Of 39 participants receiving Te, almost
30% experienced skin irritation; one withdrew (GHTe
group). One placebo-treated participant withdrew due to
insomnia. There was no increase in the prevalence of im-
paired glucose tolerance (fasting glucose, 6.1 nmol/liter).
No participant developed diabetes. PSA did not increase
during the study. No participant developed polycythemia.
Relationship between hormonal changes and outcome
measures
At baseline, a negative correlation was found between VF
area and Te levels (r  0.23; P  0.033), but no significant
correlations were found between Te or IGF-I levels and any
other baseline measures. At the end point, changes in IGF-I
correlated positively with changes in LBM (r  0.53; P 
0.001) and VO2max (r 0.44; P 0.001) and negatively with
changes in total fat mass (r  0.34; P  0.003). No corre-
lation was found between changes in VO2max and LBM.
FIG. 2. A, The effects of placebo (Pl), GH, Te, and combined GH and
Te on IGF-I levels during the study. B, The effects of placebo, GH, Te,
and combined GH and Te on Te levels from 0–6months (f, 0 months;
, 6 months). *, P  0.05.
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Discussion
The results show that 6-month administration of rhGH
and Te, in contrast to either given alone, has beneficial effects
on body composition and cardio-respiratory fitness for
healthy elderly men selected for age-relative low IGF-I and
Te levels. Furthermore, this is the first double-blind, placebo-
controlled trial to show that such effects can be produced by
individually adjusted, physiological supplementation of GH
with Te. We selected volunteers with relatively low age-
specific IGF-I levels and successfully increased these to the
upper half of the age-specific reference range using a novel
dose titration regimen rather than a weight-based regimen
for rhGH administration. There were two reasons for this:
firstly, to avoid short-term side effects, and secondly, to
assess the effectiveness of a near-physiological rhGH re-
placement dose. This approach produced fewer side effects
than previous studies using traditional weight-based rhGH
regimens (13).
LBM increased similarly in both GH and GHTe groups.
The 28% greater total fat mass decrease with GHTe than GH
alone suggests synergy between GH and Te. These effects
resemble those of rhGH given alone at higher doses (13, 14)
or combinedwith Te (22, 23), the smaller body compositional
changes being consistent with lower rhGH doses and the
titration period reducing the total exposure to target rhGH
doses.
The absence of significant LBM or fat changes on Te alone
differs from previous studies of elderly or hypogonadal men
(16, 17, 30). Te levels achieved in our study compare to Te
levels reported in similar studies in which Te was adminis-
tered in the form of weekly im injections (11, 21). In both of
these studies, significant changes in LBM have been re-
ported. The anabolic effect of Te on LBM has been shown
recently in a series of studies to be highly dose and Te
concentration dependent (31). A lower weekly concentration
of administered Te achieved with transdermal patches, com-
pared with the spikes and troughs seen with weekly injec-
tions of Te, could explain this discrepancy. In addition,
higher baseline Te values or shorter duration may have con-
tributed. Convenience regarding the administration of the
treatment and a more physiological sex hormone profile
associated with administration by patches influenced our
choice of patches instead of im Te in this study.
Midthigh muscle CSA increased most (7%) in the GHTe
group. Skeletal muscle mass increased in GH-deficient
(GHD) adults given rhGH (32) and in hypogonadal men
given Te (30), but this study is the first to show this effectwith
computed tomography scanning in healthy elderly men.
As expected in ageing men, we observed small decreases
in muscle strength over time. Previous studies of healthy
elderlymen given GH or Te have demonstrated insignificant
or marginal increases (14, 16, 22, 33, 34), and demonstrable
strength increases in treated adult GHD patients take up to
12–24 months (35). It has been argued that differences in the
methods employed to measure isokinetic muscle strength
may well explain the contradictory results of similar studies
(36). Indeed, when isokinetic muscle strength was measured
by one repetition maximum exercise, an increase in muscle
strengthwas noticed in hypogonadalmen (11) and in healthy
elderly men after Te and GH plus Te administration (17, 21,
22). Conversely, when muscle strength was measured using
an open kinematic chain exercise dynamometer, muscle
strength failed to increase (16, 30). In our study, muscle
strength was measured with an open kinematic chain exer-
cise dynamometer (Kin-Com); thus, the single finding of
significantly increased knee flexion strength with the more
potent GH and Te combination after a shorter treatment
duration is an important positive finding.
FIG. 3. The effects of placebo, GH, Te,
and combined GH and Te on LBM (A),
fat mass (B), percent change from 0 to 6
months in the midthigh CSA (C), and
VO2max (D). InA, B, andD:f, baseline;
, 6 months. *, P  0.02; **, P  0.01;
***P  0.001.
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Improved cardiovascular fitness (VO2max), observed only
in the GHTe group, accords with the findings of a similar
study (22). Increased muscle mass probably contributed to
this. The smaller LBM and CSA increases with GH alone
were not associatedwith significant strength or fitness gains,
but this may also have been due to the relatively short treat-
ment period. Discordance of muscle mass, strength, and fit-
ness gains has also been noted in treated adult GHD patients
(33, 37). Increased fiber size was associated with gains in
submaximal aerobic capacity and improved walking ability,
but not strength (38). Different physiological roles of fiber
types may be a factor; in untreated GHD adults, correlations
existed between proportional total type I fiber CSA and
VO2max and between proportional total type II fiber CSA
and strength (39). Thus, differing treatment effects on fiber
types may explain some of these findings.
Aging is associated with a progressive decline of physical
activity and VO2max (37). Although exercise can increase
bothmusclemass and strength in elderly people, the dropout
rate from exercise programs is high. The therapeutic achieve-
ment of increased VO2max is a very important result. In
suitable elderly subjects, it may be possible to ameliorate the
ageing/disuse muscle strength decline by restoring exercise
capacity.
Although one participant withdrew from the study be-
cause of carpal tunnel syndrome, other rhGH side effects
were minor and reversed within days of dose reduction.
None of the rhGH-treated participants developed impaired
glucose tolerance or diabetes, in contrast with the high in-
cidence of diabetes reported in a similar study using higher
doses of rhGH (22). Lower rhGH doses might improve in-
sulin sensitivity by dissolvingVFwithout first going through
a phase of insulin resistance (40). PSA and hemoglobin re-
mained unchanged in Te-treated individuals.
Most patient-reported outcomes showed no significant
change, although caution is prudent when interpreting re-
sults from small samples. Although those in the Te group
reported a worsening negative impact of age-related hor-
mone deficiency on quality of life over time, both GH groups
indicated improvements despite increased bodily pain in the
GH-only group.
The main limitation of this study was its short duration,
TABLE 2. Effects of treatment on muscle strength
Peak torque (Nm) Pl (n  16) GH (n  16) Te (n  21) GHTe (n  16)
Knee extension at 60°sec1
Baseline 116.8 (8.1) 121.8 (8) 115.6 (4.7) 134 (6)
End 107 (6) 111.7 (9.2) 107.2 (4.9) 127.3 (5.9)
Change 9.81 10.07 8.45 (4.2) 6.7 (5.1)
P value 0.84 0.80 0.19
Knee extension at 90°sec1
Baseline 104.1 (7.5) 114.8 (8.5) 108.5 (4.9) 123.8 (8)
End 94.8 (4.5) 101.6 (8.2) 99.8 (5) 116.8 (4.4)
Change 9.25 (4.1) 13.2 (6.6) 9.1 (4.6) 7 (4.9)
P value 0.82 0.6 0.05
Knee extension at 120°sec1
Baseline 98.6 (6.5) 107.6 (7.2) 97.7 (4.6) 108.5 (4.5)
End 89.6 (4.1) 98.8 (7.8) 92.2 (4.4) 102.9 (4.3)
Change 9.06 (4.2) 8.7 (5.2) 5.4 (4.4) 5.5 (4.5)
P value 0.44 0.43 0.12
Knee flexion at 60°sec1
Baseline 67.6 (6.04) 74.9 (3.8) 68.05 (3.1) 77.3 (4.3)
End 66.8 (6.1) 72.5 (5.7) 63.8 (2.8) 76.2 (5.9)
Change 0.8 (3.8) 2.3 (3.4) 4.2 (2.4) 1 (4.05)
P value 0.97 0.53 0.69
Knee flexion at 90°sec1
Baseline 68.5 (6.2) 78.5 (4.3) 69.2 (3.3) 81.4 (4.3)
End 70.4 (5.1) 74 (5.2) 62.4 (3.2) 82 (5.2)
Change 1.9 (3.3) 4.5 (2.6) 6.08 (2.4) 0.5 (4)
P value 0.39 0.05 0.63
Knee flexion at 120°sec1
Baseline 73.8 (6.8) 80.7 (4.9) 73.09 (3.3) 80.8 (3.9)
End 70.6 (4.9) 76.1 (4.8) 66.6 (2.8) 84.8 (5.4)
Change 3.1 (4.7) 4.5 (2.3) 6.4 (2.9) 4.06 (3.6)
P value 0.82 0.44 0.03
Isometric knee (N)
Baseline 418.6 (27.1) 448.1 (33.4) 433.1 (16.8) 483 (20.5)
End 408.2 (23.6) 442.2 (35.8) 427.5 (24.6) 476 (22.5)
Change 10.4 (17.6) 5.9 (24.5) 5.6 (22.2) 6.6 (19.4)
P value 0.59 0.58 0.33
Hand grip
Baseline 37.4 (1.6) 37.4 (1.7) 34.6 (1.1) 38.1 (2.1)
End 36.7 (1.6) 37.3 (1.8) 35.3 (1.1) 38.1 (2)
Change 0.08 (0.5) 0.6 (0.7) 0.03 (0.8)
P value 0.92 0.13 0.92
n, Number of participants who completed 6 months; Nm, newton meter; N, newton. All values are presented as mean (SE). P values represent
changes in each treatment group when compared to placebo (Pl).
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because studies in adults with GHD suggest that the benefits
of GH replacement accrue over a number of years. Neither
rhGH nor Te yet has an established clinical role in older men
without frank deficiency, but our study suggests that com-
bining an individually tailored physiological low-dose GH
administrationwith a standard Te dosemay be feasible, safe,
effective, and clinically useful. Additional longer-term trials
with the power to define surrogate end points of frailty, such
as falls or dependency, are needed. The maintenance of true
double-blind conditions in a study such as this is always
difficult, but we believe that the steps we took to maintain
such conditions were successful.
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